Dr Jeffrey Ross presents at ecancer's Milan Summit on Precision Medicine 2018 about the uses and limitations of NGS in precision medicine.
He highlights important limiting factors and examples of mutations which require highly sensitive technology.
He also goes in to detail regarding the FoundationOne assay.
Overall, Dr Ross encourages the marrying of clinical and genomic data to drive discovery in cancer research.
The webcast has been supported by an unrestricted educational grant from Roche Foundation Medicine